

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-34. (Cancelled)

35. (Currently Amended) A method for identifying a compound that modulates production of a Th2-associated cytokine in a cell, comprising

providing an indicator composition comprising (i) a maf family protein ~~comprising an amino terminal transactivation domain and a carboxy terminal basic leucine zipper region which binds to a MARE regulatory sequence of a Th2 associated cytokine gene~~; and (ii) a target DNA comprising a MARE regulatory sequence of a Th2-associated cytokine gene to which said maf family protein binds, wherein said indicator composition is an indicator cell or an acellular preparation;

contacting the indicator composition with each member of a library of test compounds;

selecting from the library of test compounds a compound of interest that modulates binding of said maf family protein to said target DNA; and

determining the effect of the compound of interest on the production of a Th2-associated cytokine in a cell to thereby identify a compound that modulates production of the Th2 cytokine.

36. (Previously Presented) The method of claim 35, wherein the maf family protein is c-Maf.

37. (Cancelled)

38. (Previously Presented) The method of claim 35, wherein the Th2-associated cytokine gene is an interleukin-4 gene.

39. (Previously Presented) The method of claim 35, wherein the effect of the compound of interest on Th2-associated cytokine production is determined by determining the effect of the compound on development of T helper type 1 (Th1) or T helper type (Th2) cells.

40. **(Currently Amended)** The method of claim 35, wherein the maf family protein is ~~selected from the group consisting of: v-maf, Nrl and p18.~~

41. **(Cancelled)**

42. **(Previously Presented)** The method of claim 35, wherein the target DNA comprises the regulatory sequence of an interleukin-4 gene.

43. **(Previously Presented)** The method of claim 35, wherein the indicator composition is an indicator cell.

44. **(Previously Presented)** The method of claim 43, wherein the indicator cell is a lymphoid cell.

45. **(Previously Presented)** The method of claim 44, wherein the lymphoid cell is a Th2 cell.

46. **(Previously Presented)** The method of claim 44, wherein the lymphoid cell is a Th1 cell.

47. **(Previously Presented)** The method of claim 44, wherein the lymphoid cell is a B cell.

48. **(Previously Presented)** The method of claim 43, wherein the indicator cell is a non-lymphoid mammalian cell.

49. **(Previously Presented)** The method of claim 43, wherein the indicator cell is a yeast cell.

50-55. **(Cancelled)**

56. **(Previously Presented)** The method of claim 44, wherein lymphoid cell is a helper precursor (Thp) cell.

57. (New) The method of claim 35, wherein the indicator composition is an acellular preparation.

58. (New) The method of claim 35, wherein the maf family protein is c-maf or v-maf and the Th2-associated cytokine gene is an IL-4 gene or an IL-10 gene.

59. (New) The method of claim 35, wherein the Th2-associated cytokine gene is an interleukin-10 gene.

60. (New) The method of claim 35, wherein the production of IL-4 is modulated.

61. (New) The method of claim 35, wherein the production of IL-10 is modulated.

62. (New) The method of claim 35, wherein the maf family protein is recombinantly expressed in a cell.

63. (New) The method of claim 35, wherein the cell does not naturally express the maf family protein.

64. (New) The method of claim 35, wherein the regulatory sequence comprises about 3 kb of the upstream regulatory sequences of the IL-4 gene.

65. (New) The method of claim 35, wherein the regulatory sequence comprises from about nucleotide -157 to about residue +58 relative to the start site of transcription of +1 of the IL-4 promoter.

66. (New) The method of claim 35, wherein Th2-associated cytokine production is assessed by detecting cytokine mRNA.

67. (New) The method of claim 35, wherein Th2-associated cytokine production is assessed by detecting the cytokine protein.